Yes, they seem to have issues. There was some debating on twitter, but the story was big probably because the crisper babies. Since the controversy with that, people love to comment how wrong he was for doing it; probably will set crisper back some and some of these other as well. If I were CYDY, I would quickly do a mice studies, ccr5-, ccr5+, ccr5+ with leronlimab, give the flu virus to all three groups and see the differences.

I saw that article, thanks. After the article last week, there was some issues raised by Sean Harrison who had access to the database and ran his own analysis (one of the biggest it was not even the delta 32 exactly)
https://twitter.com/Sean_Harrison2

The authors responded here:
https://twitter.com/ras_nielsen/status/1136383539321090048

Quote:

---

I feel obligated to have to comment on the many news stories arguing that the “CRISPR babies will likely die young” as an interpretation of our study (https://www.nature.com/articles/s41591-019-0459-6 …). This interpretation is not valid or responsible. 1/4

---

Quote:

---

First, the effect size we estimate is not nearly strong enough to warrant such a conclusion. Also, the confidence intervals are very large. I have had a hard time getting the latter point out in the press stories. 2/4

---

Quote:

---

Secondly, you cannot transfer the effects we see in the UK Biobank to people in China because of differences in environment and genetic background. 3/4

---

Quote:

---

Thirdly, as far as we know, one of the individuals is heterozygous and none of them have the exact delta32 mutation , but instead have other mutations aimed at mimicking the effect of delta32. 4/4

---

Quote:

---

I would also like to emphasize that the tradeoff for somatic treatment of HIV infected individuals obviously is quite different as pointed out in this tweet. Our results should not be used to argue against such therapies.

---